Medtronic plc has announced FDA approval and US launch of the Intellis platform for the management of certain types of chronic intractable pain. The Intellis platform was designed to overcome limitations with current spinal cord stimulation (SCS) systems, such as battery performance, and can power the Evolve workflow which standardizes guidance and balances high-dose (HD) and low-dose (LD) therapy settings. It can also record and track patient activity 24/7 and is managed on the Samsung Galaxy Tab S2 tablet interface, enabling physicians to address the subjective and personal nature of chronic pain by monitoring progress and making modifications to better suit their patients' therapy needs.
Back problems are 1 of the top 10 most expensive medical conditions, with an estimated 30% of the 300,000 patients annually who undergo lumbosacral spine procedures developing chronic intractable pain. Chronic pain can negatively impact all aspects of a person's life, yet it remains under-recognized and undertreated. Neurostimulation has been proven to provide effective long-term pain relief and improve quality of life, in addition to being a treatment option for patients interested in trying a non-drug alternative.
Medtronic plc is headquartered in Dublin, Ireland.
Medtronic announces FDA approval and US launch of next generation spinal cord stimulator for chronic pain management. [news release]. Dublin, Ireland: Medtronic plc. September 18, 2017. http://newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=2301240. Accessed September 27, 2017.
This Week's Must Reads
Higher Cortisol Linked with Lower Brain Volume, Neurology; ePub 2018 Oct 24; Echouffo-Tcheugui, et al
Ischemic Stroke Transfers in the Northeastern US, J Stroke Cerebrovasc Dis; ePub 2018 Oct 30; Zachrison, et al
Predictors of Recurrent Hospitalizations Post-TIA, J Stroke Cerebrovasc Dis; ePub 2018 Oct 17; Yousufuddin, et al
Sleep Apnea Associated with Less Healthful Diet, Sleep; ePub 2018 Oct 22; Reid, Maras, Shea, et al
Hypertension, Obesity, Cognitive Decline Examined , Alzheimers Dement; ePub 2018 Oct 24; Clark, et al
Must Reads in FDA Actions
FDA Approves Ajovy for Migraine in Adults, Teva Pharmaceutical news release; 2018 Sep 14
FDA Approves Tiglutik for Treatment of ALS, ITF Pharma news release; 2018 Sep 6
FDA Approves Diacomit for Treatment of Seizures, Biocodex news release; 2018 Aug 23
FDA Approves Drug for Rare Peripheral Nerve Disease, FDA Web site; 2018 Aug 10
FDA Approves Xeomin for Excessive Drooling, Merz North America news release; 2018 Jul 3